Aurinia Pharmaceuticals Inc (AUPH) Shares Jump 19.5% on Positive Phase 2 Results for Voclosporin

Share

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) are up big today after it was announced that the company achieved positive results in their AURION study, which examined a Lupus Nephritis treatment. Seven out of seven patients who received a multi-target therapy with voclosporin, achieved at least a 25% reduction of proteinuria at the 8 week mark. The mean decrease was 72%. This is great news for those who where hoping to see some good results in this phase 2 study. The results were even better than many had hoped for.

“We are encouraged by these results. This is the first time voclosporin has been used in this particular patient population.” said Dr. Neil Solomons, MD, Chief Medical Officer of Aurinia Pharmaceuticals Inc. “It appears that this data supports our hypothesis that utilizing a multi-targeted approach to treating LN with voclosporin can help patients suffering from this disease. We are very excited to see the results from the 265 patient AURA study later this year.”

The stock is up 19.53% or $0.43 following the news, hitting $2.63 per share. About 775,974 shares traded hands or up 2674.90% from the average. AUPH has declined 31.78% since July 2, 2015 and is currently downtrending. It has underperformed the S&P500 by 22.30%.

Aurinia Pharmaceuticals Inc. is a Canada is a clinical stage pharmaceutical company. The company has a market cap of $70.71 million. The Firm is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). It currently has negative earnings. Voclosporin is an oral drug, administered twice daily.

#focuskw=’Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’##metadesc=’Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) are up big today after it was announced that the company achieved positive results in their AURION study, which examined a Lupus Nephritis treatment. Seven out of seven patients who received a multi-target therapy with voclosporin, achieved at least a 25% reduction of proteinuria at the 8 week mark. The mean decrease was 72%. This is great news for those who where hoping to see some good results in this phase 2 study. The results were even better than many had hoped for.

“We are encouraged by these results. This is the first time voclosporin has been used in this particular patient population.” said Dr. Neil Solomons, MD, Chief Medical Officer of Aurinia Pharmaceuticals Inc. “It appears that this data supports our hypothesis that utilizing a multi-targeted approach to treating LN with voclosporin can help patients suffering from this disease. We are very excited to see the results from the 265 patient AURA study later this year.”

‘##metarobot=’index’##newskw=’Aurinia Pharmaceuticals Inc news,Aurinia Pharmaceuticals Inc – (NASDAQ:AUPH),NASDAQ:AUPH Analyst rating analysis,Stock Analysis,Outlook and potential,AUPH Price change and trend,AUPH stock update’##sitemap=’include’##skipsocial##stockticker=’NASDAQ:AUPH’#

COMMENTS: